Table 6.
(a) The incremental costs, benefits and cost-effectiveness ratios (ICERs) for treatment alternatives in comparison with 1-year course of lamivudine of HBeAg-positive chronic hepatitis B (CHB); (b) The ICERs for treatment alternatives in comparison with 1-year course of lamivudine of HBeAg-negative CHB
| Treatment alternatives | Cost (S$) | Life year gained | QALY | Cost per Life Year gained (S$/LY) | Cost per QALY gained (S$/QALY) |
|---|---|---|---|---|---|
| (a) | |||||
| IFN | 4570.91 | −0.050 | −0.209 | nv | nv |
| PEG-IFN (1 year) | 16 968.32 | 0.242 | 0.251 | 70 161.69 | 67 540.78 |
| Adefovir (1 year) | 735.09 | −0.048 | −0.020 | nv | nv |
| Lamivudine (5 years) | 5783.60 | 0.320 | 0.313 | 18 073.04 | 18 507.18 |
| Adefovir (5 years) | 8989.51 | 0.414 | 0.422 | 21 689.93 | 21 313.88 |
| Lamivudine + adefovir as rescue (5 years) | 6207.56 | 0.548 | 0.535 | 11 319.95 | 11 604.85 |
| Adefovir + lamivudine as rescue (5 years) | 8597.43 | 0.481 | 0.494 | 17 864.69 | 17 403.02 |
| (b) | |||||
| PEG-IFN (1 year) | 17 856.93 | 0.017 | −0.082 | 1 065 894.63 | nv |
| Adefovir (1 year) | 934.59 | −0.109 | −0.097 | nv | nv |
| Lamivudine (5 years) | 8878.72 | 0.508 | 0.509 | 17 461.19 | 17 453.01 |
| Adefovir (5 years) | 11 542.99 | 1.106 | 1.097 | 10 439.73 | 10 524.11 |
| Lamivudine + Adefovir as rescue (5 years) | 8822.34 | 1.213 | 1.172 | 7271.76 | 7528.61 |
| Adefovir + Lamivudine as rescue (5 years) | 11 183.36 | 1.262 | 1.248 | 8861.37 | 8960.64 |
nv, alternative treatments dominated by 1-year course of lamivudine (i.e. better outcomes achieved at lower costs when lamivudine is used).